
Enable job alerts via email!
A leading contract research organization in Dundee is seeking an Assistant Technician 1 to perform laboratory tasks and support study operations. The ideal candidate should have National 5 qualifications with a science component and a strong attention to detail. The role offers both a 12-month fixed term contract and permanent opportunities. Salary is £23,842.35 per annum.
For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.
The BioSciences Lab Services Department currently has an exciting career opportunity for an Assistant Technician 1 to join our team. In this lab based role, the successful candidate will have the opportunity to learn new and varied laboratory skills and techniques whilst building a career within the scientific industry. We have both a 12 month fixed term contract, and a permanent opportunity available.
The successful candidate will work within a busy, dynamic team which operates across a variety of study types, covering the pharmaceutical, veterinary pharmaceutical and chemical/agrochemical industries by evaluating the absorption, distribution, metabolism and excretion of new chemical and biological entities in test systems (animals, plants and soils) required for the development of new compounds/drugs before they get to market.
You will be required to take responsibility for the following activities (for which full training will be given):
The following are minimum requirements related to theAssistant Technician 1position:
Salary will be £23,842.35per annum.
The closing date is 29 October 2025.
Charles River is committed to helping our partners expedite their preclinical drug development with exceptional safety assessment services, state-of-the-art facilities and expert regulatory guidance. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and avoid roadblocks for a smooth, efficient journey to market. Each year approximately 120 investigational new drug (IND) programs are conducted in our Safety Assessment facilities.
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.
For more information, please visit www.criver.com.